2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 115

Composite Ultrasound Score in Spondyloarthropathies
Abstract Number: 182

Comprehensive Analysis of Protein Expression in Peripheral Blood Mononuclear Cells From Patients with Behcet’s Disease
Abstract Number: 430

Comprehensive Microrna Analysis Identifies Mir-24, Mir-26a, and Mir-125a-5p As Plasma Biomarkers for Rheumatoid Arthritis
Abstract Number: 869

Concepts Which Determine Health in a Positive Way Are Important to People with Rheumatoid Arthritis and Are Covered by Some Patient-Reported Outcome Instruments
Abstract Number: 470

Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Abstract Number: 2181

Concomitant Atheosclerosis and Impaired Bone Health in Patients with Primary Sjogren’s Syndrome
Abstract Number: 1101

Condroitin Sulfate Decreases Chemokine Levels and Synovitis in knee osteoarthritis Patients
Abstract Number: 2303

Confirmation of TNIP1 As a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study
Abstract Number: 2590

Consolidating Knowledge, Comprehension, Application and Analysis in Rheumatology Education by Use of an in-House Electronic Module (Web-based Rheumatology Case Scenarios)
Abstract Number: 2609

Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study
Abstract Number: 913

Consultation Prevalence of Osteoarthritis in Southern Sweden
Abstract Number: L4

Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Abstract Number: 2137

Contribution of Disease Activity, Joint Damage and Comorbidity to Impairment (SOFI) and Disability (HAQ) in Rheumatoid Arthritis Patients Over 20 Years
Abstract Number: 1993

Contribution of Lifestyle Factors to Healthy-Adherer Bias in Prevalent Users of Osteoporotic Drugs
Abstract Number: 1228

Contributions of Inflammation, Inactivity, and Low Dose Prednisone Use to Skeletal Muscle Insulin Resistance in Well-Controlled Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].